Spots Global Cancer Trial Database for Hepatocellular Carcinoma (HCC)_Torisel_
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hepatocellular Carcinoma (HCC)_Torisel_
Official Title: Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression
Study ID: NCT01251458
Conditions
Interventions
Study Description
Brief Summary: This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, , Hong Kong
Contact Details
Name: Winnie Yeo, MD, FRCP
Affiliation: Department of Clinical Oncology, The Chinese University of Hong Kong
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
